These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 38831548

  • 1. Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea.
    Pakdaman SF, Samadi A, Fattahi M, Naeimifar A, Ardehali FA, Ketabi Y, Nasrollahi SA, Firooz A.
    J Cosmet Dermatol; 2024 Sep; 23(9):2973-2981. PubMed ID: 38831548
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.
    Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N.
    J Drugs Dermatol; 2017 Sep 01; 16(9):909-916. PubMed ID: 28915286
    [Abstract] [Full Text] [Related]

  • 3. Interventions for rosacea.
    van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L.
    Cochrane Database Syst Rev; 2015 Apr 28; 2015(4):CD003262. PubMed ID: 25919144
    [Abstract] [Full Text] [Related]

  • 4. Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States.
    Taieb A, Stein Gold L, Feldman SR, Dansk V, Bertranou E.
    J Manag Care Spec Pharm; 2016 Jun 28; 22(6):654-65. PubMed ID: 27231793
    [Abstract] [Full Text] [Related]

  • 5. Oral tranexamic acid treats papulopustular rosacea by improving the skin barrier.
    Xu Z, Yu B, Xu B, Ye S, Qing Y, Zhao B, Hong S, Wu N, Wu J.
    J Cosmet Dermatol; 2024 Sep 28; 23(9):2918-2926. PubMed ID: 38712728
    [Abstract] [Full Text] [Related]

  • 6. Rosacea with persistent facial erythema and high Demodex density effectively treated with topical ivermectin alone or combined with oral carvedilol.
    Huang HP, Hsu CK, Lee JY.
    Dermatol Ther; 2021 Mar 28; 34(2):e14899. PubMed ID: 33605018
    [Abstract] [Full Text] [Related]

  • 7. A novel moisturizer with high sun protection factor improves cutaneous barrier function and the visible appearance of rosacea-prone skin.
    Baldwin H, Santoro F, Lachmann N, Teissedre S.
    J Cosmet Dermatol; 2019 Dec 28; 18(6):1686-1692. PubMed ID: 30803131
    [Abstract] [Full Text] [Related]

  • 8. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea.
    Schaller M, Kemény L, Havlickova B, Jackson JM, Ambroziak M, Lynde C, Gooderham M, Remenyik E, Del Rosso J, Weglowska J, Chavda R, Kerrouche N, Dirschka T, Johnson S.
    J Am Acad Dermatol; 2020 Feb 28; 82(2):336-343. PubMed ID: 31150711
    [Abstract] [Full Text] [Related]

  • 9. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
    Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M, Brimonidine Phase II Study Group.
    Br J Dermatol; 2012 Mar 28; 166(3):633-41. PubMed ID: 22050040
    [Abstract] [Full Text] [Related]

  • 10. Ivermectin treatment in rosacea: How novel smartphone technology can support monitoring rosacea-associated signs and symptoms.
    Schaller M, Riel S, Bashur R, Kurup N, Schnidar H, Fehrenbacher B.
    Dermatol Ther; 2022 Nov 28; 35(11):e15869. PubMed ID: 36177738
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
    Fowler J, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M.
    J Drugs Dermatol; 2013 Jun 01; 12(6):650-6. PubMed ID: 23839181
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
    Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, Kempers SE, Alvandi N, Weng E, Berk DR, Ahluwalia G.
    J Am Acad Dermatol; 2018 Jun 01; 78(6):1156-1163. PubMed ID: 29409914
    [Abstract] [Full Text] [Related]

  • 18. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea.
    Schaller M, Gonser L, Belge K, Braunsdorf C, Nordin R, Scheu A, Borelli C.
    J Eur Acad Dermatol Venereol; 2017 Nov 01; 31(11):1907-1911. PubMed ID: 28653460
    [Abstract] [Full Text] [Related]

  • 19. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
    Layton AM, Schaller M, Homey B, Hofmann MA, Bewley AP, Lehmann P, Nohlgård C, Sarwer DB, Kerrouche N, Ma YM.
    J Eur Acad Dermatol Venereol; 2015 Dec 01; 29(12):2405-10. PubMed ID: 26416154
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.